GERD Treatments Need Further Study, BlueCross BlueShield Assessment Finds
This article was originally published in The Gray Sheet
Executive Summary
Gastroesophageal reflux disease reimbursement trials should include control groups to discount placebo-effects, according to the BlueCross BlueShield Technology Evaluation Center